Platelets play a key role in the pathogenesis of atherosclerosis and acute coronary syndromes and antiplatelet therapy offers a clinical benefit. Although aspirin is the most widely used agent, there are several conditions in which aspirin may fail to provide a full antithrombotic benefit. Furthermore, data concerning the relationship between platelet function, aspirin, and the associated risk factors are limited.
thromboxane A 2 (TxA 2 ) which play roles in thrombus formation and increase vascular tone. Platelet derived growth factors lead to a proliferation of vascular cells. Arterial thrombi are composed predominantly of platelets at the sites of atherosclerosis under high shear. [1] [2] [3] Antiplatelet therapy offers a clinical benefit in atherosclerotic vascular disease and arterial thrombosis. Aspirin is the most widely used agent to reduce platelet function. Aspirin inhibits platelet aggregation by the irreversible prevention of TxA 2 formation. 4, 5) The thromboxane pathway is not the only mechanism that regulates platelet function, and platelets may be stimulated by a variety of different pathways. 6) Several animal and clinical experiments have exposed some limitations of aspirin. ADP, high epinephrine, and shear-induced platelet aggregation may overcome the effect of aspirin. Individual patient responses to aspirin also may vary. [7] [8] [9] Recent advances in our understanding of platelet activation have shown the need for further investigations on the antithrombotic effect of aspirin.
We conducted a double blind study to evaluate platelet aggregation in patients with and without coronary artery disease (CAD) and in relation to risk factors such as hypertension, hyperlipidemia, diabetes mellitus, and smoking. The effects of aspirin on collagen and ADP-induced platelet aggregation in relation to risk factors are also discussed.
MATERIALS AND METHODS

Patients:
Two hundred consecutive patients who had undergone coronary angiography due to suspected CAD in the Department of Cardiology of Türkiye Yüksek Ihtisas Hospital between November 1999 and May 2000 were prospectively enrolled in this study. One hundred and forty-two were male and 58 were female. Their ages ranged from 31-75 years (mean=56.1 years). Clinical features: The demographic and clinical features analyzed included age, sex, weight, risk factors for coronary artery disease (hypertension, diabetes mellitus, current cigarette smoking, hypercholesterolemia, and family history of premature coronary artery disease), and history of previous myocardial infarction. Blood glucose and total serum cholesterol levels were also measured. Only patients using 300 mg/day aspirin as an antiplatelet drug were included in the study. Patients receiving doses lower or higher than 300 mg and patients using any other antithrombotic agents alone or in combination with aspirin were excluded from the study. All patients gave written informed consent and the study protocol was approved by the Ethical Committees of both institutions. Coronary angiography: Selective coronary angiography was performed in all study patients using the Judkins technique in multiple standard and angulated views for optimal visualization of diseased segments. The coronary angiograms were analyzed by two independent angiographers for the extent of CAD in a random sequence who were blinded to the clinical data. Interobserver variation was investigated by kappa (K) statistics. High intraobserver variability was found between two observers for extent of CAD (K=0.92, P<0.0001). In cases of noncoincidence, the angiographers reached a consensus. Patients were categorized as having single or multi-vessel disease when 50% or more narrowing of an intraluminal diameter was present in one or more coronary arteries or a major branch, or both. The absence of any narrowing in diameter was considered to be evidence of a normal coronary artery. The patients were divided into three groups. Patients with normal coronary arteries constituted the control group (group 1). Patients having single-vessel disease were included in group 2, and those with two or more vessel disease were included in group 3. Blood sampling: All blood samples were obtained between 8:30-10:30 a.m. from the femoral artery just before the coronary angiography procedure. Samples for the platelet aggregation tests were collected into siliconized tubes, where the blood was mixed with 3.8% sodium citrate at a ratio of 9:1. Blood was collected into a 1:9 volume of 1% EDTA for complete blood counts. Platelet aggregation: Platelet aggregation was evaluated by the electrical impedance method in whole blood using a Chronolog (Model 560WB Chronolog Corp PA, USA) aggregometer. 10) Five hundred µL of blood was diluted with 500 µL of physiological serum and incubated at 37°C for two minutes. A pair of platinum electrodes was placed in the blood samples. ADP (Chronolog Corp.) at a final concentration of 10 µM and collagen (Chronolog Corp.) at a final concentration of 2 µg/mL were added to the samples for in vitro activation of the platelets. The increase in impedance between the electrodes due to the aggregation of platelets on the electrodes was recorded. The response was measured as the maximal change in impedance (maximal intensity of platelet aggregation). WBC, platelet count, and hematocrit were determined using a Coulter T890 Counter. Statistics: Data are expressed as mean±SD for continuous variables and proportions for categorical data. A P value <0.05 was considered significant. To compare the means of variables, the unpaired Student t test and Mann Whitney U test were used. The chi-square test was used to compare the proportions. The kappa statistic was used to assess the intraobserver variability. Hypertension, diabetes mellitus, smoking, family history of ischemic heart disease, white blood cell count, count platelet count, hematocrit, and ADP and collagen-induced platelet aggregation were estimated as potential risk factors by univariate analyses. Variables chosen for further multivariate modeling (logistic regression) were significant at the P=0.10 level in univariate analyses. The relationships between blood glucose, plasma fibrinogen level, and total cholesterol level with the maximal intensity of ADP and collagen-induced platelet aggregation were performed using Spearman's Rank correlation. An SPSS statistical software package program (version 9.0) was used to perform all statistical calculations.
RESULTS
Of the total of 200 cases, 75 (37.7%) had normal coronary arteries (group 1), 46 (23.1%) had 1-vessel disease, (group 2) and the remaining 78 cases (39.2%) had multivessel disease (group 3). One hundred and eight of the cases were using aspirin at a daily dose of 300 mg for at least 1 week. The demographic characteristics and prevalence of the risk factors for CAD in both groups are shown in Table I . The mean age of groups 2 and 3 was significantly higher than group 1 (P<0.05). The ratio of males to females in Group 2 and 3 was significantly higher than in group 1 (P<0.05). Of the risk factors examined, hypertension was correlated to CAD with the highest odds ratio, followed in order by hyperlipidemia, family, history and smoking. Table II shows the maximal intensity of ADP and collagen-induced platelet aggregation (ohm) for controls, single, and multivessel disease, and the effect of aspirin. Aspirin usage reduced collagen-induced platelet aggregation in the control subjects, while it had no effect on collagen-induced aggregation of patients with single or multivessel disease. There was no significant difference in ADPinduced platelet aggregation between the two patient groups.
The maximal intensity of ADP and collagen-induced platelet aggregation in the patients (Groups 2 and 3) not using aspirin is presented in Table III according to subgroups for hyperlipidemia, hypertension, diabetes mellitus, family history, and smoking. The maximal intensity of collagen-induced platelet aggregation was higher in smokers (P<0.05). Although platelet aggregation seems to be higher in diabetic patients, the difference was not found to be statistically significant (P>0.05). No correlation was found between platelet aggregation and blood glucose (P>0.05). Collagen-induced platelet aggregation was 5.6±6.4 ohm in non-hypertensive patients (n=24), and 7.3±7.4 ohm in hypertensive patients (n=15). The increase in maximal intensity of collagen-induced platelet aggregation in the hypertensive patients was not statistically significant. The other risk factors were not found to be unrelated to ADP and collagen-induced platelet aggregation and aspirin. Maximal intensity of ADP and collagen-induced platelet aggregation was not correlated with total cholesterol or plasma fibrinogen levels (P>0.05).
DISCUSSION
The main findings of the present study can be summarized as follows.
(1) ADP and collagen-induced platelet aggregation in the patients were not different from those of subjects with non-stenotic coronary arteries. (2) Collagen-induced platelet aggregation in smokers was higher than in nonsmokers. Although platelet aggregation seemed to be higher in diabetic and hypertensive patients, the difference was not significant. The other risk factors examined were found to be unrelated to ADP and collagen-induced platelet aggregation. (3) Aspirin usage (300 mg/day) reduced collagen-induced platelet aggregation in subjects with nonstenotic coronary arteries, but did not affect ADP-induced platelet aggregation as expected. Aspirin did not sufficiently inhibit ADP and collagen-induced platelet aggregation in patients with single and multivessel CAD, and there was no correlation between aspirin use and risk factors.
It has been suggested that platelet hyperaggregability plays an essential role in the pathogenesis of atherosclerosis. Assessing platelet function has not been as straightforward because no single laboratory test has been developed. Whole blood electrical aggregometers are limited in their evaluation of shear-induced platelet aggregation.
11) However, the role of platelets in atherosclerosis may be strongly correlated with high shear. 1) One of the suggested causal mechanisms associated with risk factors such as hypertension, diabetes mellitus, hyperlipidemia, and smoking is enhanced platelet aggregation. Fuster, et al 3) showed that patients with diabetes mellitus, hyperlipidemia, and some forms of hypertension had increased platelet aggregability. However, in the present study platelet aggregation was slightly higher in diabetic and hypertensive patients, although the difference was not significant statistically. Also, ADP and collagen-induced platelet aggregation was not altered in relation to hypercholesterolemia. Shechter, et al 12) showed ex vivo platelet-dependent thrombosis (PDT) was significantly greater in patients with blood glucose >4.9 mmol/L while platelet aggregation was not significantly changed in relation to blood glucose. They speculated that the effect of elevated glucose might have been detectable by ex vivo PDT formation measurement, whereas no effect was detectable by in vitro platelet aggregation. It thus appears the method used to estimate platelet function is important for detecting the effects. Our data demonstrate that collagen-induced platelet aggregation in smokers was higher than in nonsmokers, and that aspirin did not inhibit smokingenhanced platelet aggregation. There are several mechanisms by which smoking may increase platelet aggregation. Nicotine (directly or indirectly) and free radicals may play essential roles in smoking-enhanced platelet aggregation. 13) Heightened platelet aggregation in habitual smokers may be one of the important mechanisms causing the increased risk of acute coronary events.
Although aspirin is accepted as the "gold standard" antiplatelet agent for the prevention of arterial thrombosis and has been shown to reduce morbidity and mortality in many clinical trials, there are several scenarios in which aspirin may fail to provide a full antithrombotic benefit. We observed that aspirin inhibited collagen-induced platelet aggregation in controls while it failed in the patients with vessel lesions. The inhibitory effect of aspirin on cyclooxygenase-catalyzed conversion of arachidonic acid into prostaglandin endoperoxides is well known. This results in inhibition of the generation of thromboxane in platelets as well the generation of downstream metabolites in platelets and vascular cells. It is suggested that in healthy subjects with functionally intact endothelium, the action of aspirin on platelets dominates at low doses. In patients with atherosclerotic vessel disease and endothelial dysfunction, platelets adhering to the subendothelium may be involved in the generation of the potent antiaggregatory agent prostaglandin by transferring precursors to vascular cells. In this case, blockage of cyclooxygenase by aspirin will reduce prostaglandin biosynthesis, and this may be relevant for aspirin resistance. 14) Many input stimuli besides TxA 2 can activate platelets in vivo and cause adhesion, aggregation, and thrombus formation. These input stimuli or agonists can act independently, and yet some can be synergistic with one another. Recent studies have revealed that platelets under blood flow can be activated by high shear stress generated in stenosed arteries. ADP released from platelets and red blood cells contributes to shear-induced platelet aggregation. 15, 16) It is postulated that ADP and shear-induced platelet aggregation overcome the antiplatelet effect of aspirin. It has also been found that high doses of epinephrine enhance platelet aggregation and sensitize ADP-induced aggregation. Experimental studies have indicated that the antiplatelet effect of aspirin is counteracted by catecholamines. 17) It is thought that aspirin may be less effective during sympathoadrenal activation.
In addition to its antithrombotic effect, other mechanisms may contribute to the clinical benefits of aspirin. It is suggested that aspirin is involved in protecting LDL from oxidative modification. Aspirin can also directly scavenge hydroxyl radicals.
5)
The improved vasodilator response to acetylcholine in patients with atherosclerosis given intravenous aspirin provides evidence that aspirin may exert its beneficial effect by improving endothelial dysfunction. 18) In conclusion, the results of the present study suggest that aspirin inhibits collagen-induced platelet aggregation in cases with normal vessels, while it fails in patients with vessel lesions. The dose of aspirin required to obtain adequate platelet inhibition also needs further detailed investigation. It is suggested that low doses of aspirin result in preferential inhibition of platelet cyclooxygenase over endothelial cyclooxygenase. The role of other mechanisms in the beneficial effect of aspirin should be examined. The use and dose of aspirin in the primary and secondary prevention of cardiovascular disease should be a clinical decision according to individual characteristics (cathecholamines, total antioxidant status, etc.) of the patient. Other new potent antithrombotic drugs may be used in combination with aspirin to complement its antiplatelet effect.
